Recently, it was recognized that an immune response develops along one of t
wo major pathways. One leads to a destructive immune response (type I), whi
le the alternative leads to a nondestructive immune response (type 2). Our
studies in animal models suggest that therapeutic vaccines induce a tumor-s
pecific type immune response while ineffective vaccines induce a type 2 res
ponse. These results have led us to examine the immune response in sentinel
lymph nodes draining tumor vaccines of patients entered onto clinical tria
ls for melanoma, breast and renal cell cancer.